Oss
Netherlands
23
2025-11-27
21
2026-05-05
These are the the leading inventors for applications assigned to Acerta Pharma B.V.:
Acerta Pharma B.V. based in Oss, NL has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS
#2 | 2024-09-26 ✅ Patent 12,448,387 granted on 2025-10-21PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE
#3 | 2024-06-06 ✅ Patent 12,263,164 granted on 2025-04-01Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#4 | 2024-01-18METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS
#5 | 2022-11-03 ✅ Patent 11,820,777 granted on 2023-11-21Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
#6 | 2022-04-28 ✅ Patent 12,024,520 granted on 2024-07-02Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
#7 | 2022-03-24 ✅ Patent 11,654,143 granted on 2023-05-23Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
#8 | 2021-12-30 ✅ Patent 11,771,696 granted on 2023-10-03Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#9 | 2020-10-22 ✅ Patent 11,110,088 granted on 2021-09-07Imidazopyrazine inhibitors of Bruton's tyrosine kinase
#10 | 2020-08-13 ✅ Patent 11,059,829 granted on 2021-07-13Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
#11 | 2019-11-14 ✅ Patent 10,858,364 granted on 2020-12-08Imidazopyrazine inhibitors of Bruton's tyrosine kinase
#12 | 2019-11-07 ✅ Patent 10,640,509 granted on 2020-05-05Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
#13 | 2019-09-26 ✅ Patent 11,090,302 granted on 2021-08-17Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#14 | 2018-11-08 ✅ Patent 10,736,893 granted on 2020-08-11Imidazopyrazine inhibitors of Bruton's tyrosine kinase
#15 | 2018-09-06 ✅ Patent 11,166,951 granted on 2021-11-09Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
#16 | 2018-07-26 ✅ Patent 10,167,291 granted on 2019-01-01Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
#17 | 2017-09-21 ✅ Patent 10,328,080 granted on 2019-06-25Therapeutic combination of PI3K inhibitor and a BTK inhibitor
#18 | 2017-08-17Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
#19 | 2017-05-18 ✅ Patent 9,949,971 granted on 2018-04-24Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
#20 | 2017-04-06 ✅ Patent 10,272,083 granted on 2019-04-30Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
#21 | 2017-02-09 ✅ Patent 9,937,171 granted on 2018-04-10Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
#22 | 2017-02-02 ✅ Patent 9,796,721 granted on 2017-10-24Crystal forms of ()-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-]pyrazin-1-yl)--(pyridin-2-yl)benzamide
#23 | 2015-03-26 ✅ Patent 9,522,917 granted on 2016-12-20Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
Also check out Acerta Pharma B.V.'s (Oss, Netherlands) applicant profile with 28 patent applications submitted.
118855 ⎘